69 related articles for article (PubMed ID: 8656673)
1. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.
Ogawa S; Kurokawa M; Tanaka T; Tanaka K; Hangaishi A; Mitani K; Kamada N; Yazaki Y; Hirai H
Leukemia; 1996 May; 10(5):788-94. PubMed ID: 8656673
[TBL] [Abstract][Full Text] [Related]
2. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Akiyama H; Kantarjian H; Jabbour E; Issa G; Haddad FG; Short NJ; Hu S; Ishizawa J; Andreeff M; Sasaki K
Int J Hematol; 2024 May; ():. PubMed ID: 38748089
[TBL] [Abstract][Full Text] [Related]
3. EVI1-mediated Programming of Normal and Malignant Hematopoiesis.
Lux S; Milsom MD
Hemasphere; 2023 Oct; 7(10):e959. PubMed ID: 37810550
[No Abstract] [Full Text] [Related]
4. JAM-A signals through the Hippo pathway to regulate intestinal epithelial proliferation.
Fan S; Smith MS; Keeney J; O'Leary MN; Nusrat A; Parkos CA
iScience; 2022 May; 25(5):104316. PubMed ID: 35602956
[TBL] [Abstract][Full Text] [Related]
5. Cancer non-stem cells as a potent regulator of tumor microenvironment: a lesson from chronic myeloid leukemia.
Mukaida N; Tanabe Y; Baba T
Mol Biomed; 2021 Mar; 2(1):7. PubMed ID: 35006395
[TBL] [Abstract][Full Text] [Related]
6. Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report.
Li X; Cai S; Zhong Z; Wang H; Wang L; You Y; Zhang M
Medicine (Baltimore); 2020 Feb; 99(9):e19256. PubMed ID: 32118733
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Hematopoiesis and Hematological Disease by TGF-β Family Signaling Molecules.
Naka K; Hirao A
Cold Spring Harb Perspect Biol; 2017 Sep; 9(9):. PubMed ID: 28193723
[TBL] [Abstract][Full Text] [Related]
8. Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report.
Lewen M; Gresh R; Queenan M; Paessler M; Pillai V; Hexner E; Frank D; Bagg A; Aplenc R; Caywood E; Wertheim G
Biomark Res; 2016; 4():14. PubMed ID: 27453784
[TBL] [Abstract][Full Text] [Related]
9. Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent
Altangerel O; Cao S; Meng J; Liu P; Haiyan G; Xu Y; Zhao M
Oncol Lett; 2015 Sep; 10(3):1694-1700. PubMed ID: 26622734
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Beaty MW; Ai D; Amin HM; McDonnell TJ; Ok CY; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2015 Oct; 126(14):1699-706. PubMed ID: 26243778
[TBL] [Abstract][Full Text] [Related]
11. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
12. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
13. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
14. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
15. Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
Bard-Chapeau EA; Szumska D; Jacob B; Chua BQ; Chatterjee GC; Zhang Y; Ward JM; Urun F; Kinameri E; Vincent SD; Ahmed S; Bhattacharya S; Osato M; Perkins AS; Moore AW; Jenkins NA; Copeland NG
PLoS One; 2014; 9(2):e89397. PubMed ID: 24586749
[TBL] [Abstract][Full Text] [Related]
16. EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.
Bard-Chapeau EA; Gunaratne J; Kumar P; Chua BQ; Muller J; Bard FA; Blackstock W; Copeland NG; Jenkins NA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):E2885-94. PubMed ID: 23858473
[TBL] [Abstract][Full Text] [Related]
17. TGF-β - an excellent servant but a bad master.
Kubiczkova L; Sedlarikova L; Hajek R; Sevcikova S
J Transl Med; 2012 Sep; 10():183. PubMed ID: 22943793
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.
Karakaya K; Herbst F; Ball C; Glimm H; Krämer A; Löffler H
Cell Cycle; 2012 Sep; 11(18):3492-503. PubMed ID: 22894935
[TBL] [Abstract][Full Text] [Related]
19. Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.
Kim TM; Ha SA; Kim HK; Yoo J; Kim S; Yim SH; Jung SH; Kim DW; Chung YJ; Kim JW
Blood Cancer J; 2011 Aug; 1(8):e32. PubMed ID: 22829191
[TBL] [Abstract][Full Text] [Related]
20. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.
Bard-Chapeau EA; Jeyakani J; Kok CH; Muller J; Chua BQ; Gunaratne J; Batagov A; Jenjaroenpun P; Kuznetsov VA; Wei CL; D'Andrea RJ; Bourque G; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2012 Feb; 109(6):2168-73. PubMed ID: 22308434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
